The Study on PLA-based nano-bio effects and its biomedical applications

分享:

简介:

  • 作者: DING Zhaowen
  • 出版日期: 2023 Aug

论文中使用的产品/服务

Quotation shows PackGene:was used as a negative control

Research Field:Coronavirus

AAV Serotype:pseudovirus

Animal or cell line strain:HEK293T

询价

摘要

Polylactic acid (PLA)-based materials with good performance in biocompatibility and biodegradation the have widely used in biomedical field, including drug delivery, tissue engineering and photothermal therapy. When the exogenous materials transmitted into the human body, various interfacial interactions between nanomaterials and biological components occur in the vasculature, pulmonary tract and gastrointestinal tract due to the long retention time and constant simulation. However, despite the efficacy of PLA-based materials, the nano-bio interaction during the transmission and the corresponding application are required to explore in depth for the rational usage and clinic guidance. This study focuses in two popular types of PLAbased materials, including two-dimensional PEGylated lamella materials and threedimensional hierarchical porous microsphere, for systemic exploration of nano-bio interaction in different disease models. The PEGylated lamella material, PEGylated poly(lactic acid) (P-PLA), despite not being internalized by vascular endothelial cells, simulated various inflammatory cytokines through L-type calcium ion channel Cav1.3, thus aggravated the atherosclerosis development while enhanced the nanomedicine extravasation and antitumor efficacy. The hierarchical porous microsphere allowed the micro-scale virus aerosol move inside through micro-scale pore, captured the virus through nano-scale pores with positive charged DOPE, thus protected the lung tissue from acute respiratory diseases such as COVID-19 and influenza A. This study clarified the complexity and diversity of nano-bio interaction in different transmission tract, and provided guidance for the rational usage of PLA-based materials in the biomedical field.

关于派真

作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IITINDBLA的各个阶段。

 

凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。

下载